Overview

Clinical Study of Ligustrazine in Treating Alcohol Addiction

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Alcohol consumption is one of the most important risk factors for chronic non-communicable diseases in the population, and it is also the main cause of death from cancer, cardiovascular disease and lung disease, causing serious health, economic and social problems. The current alcohol-abstinence drugs have limited therapeutic effects and still present a high relapse rate. It is an urgent need to develop effective drugs for the treatment of alcohol addiction. The multimodal mechanism of action of ligustrazine in the central nervous system indicates that ligustrazine is expected to be developed as a potential therapeutic drug for alcohol addiction. Our study investigated the therapeutic effect of ligustrazine on subjects with alcohol addiction and the mechanism of multimodal brain imaging by administering ligustrazine, in order to develop new targeted drugs for alcohol treatment and provide more effective diagnosis and treatment methods for clinical treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Shenzhen Kangning Hospital
Treatments:
Tetramethylpyrazine